Noxopharm Ltd V.NOX

Primary Symbol: NOXOF

Healthcare Biotechnology

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

OTCPK:NOXOF - Post by User

Noxopharm Ltd

Bullboard Posts

Comment by alixx11on Jul 08, 2010 10:00am

311 Views

Post# 17253255

RE: RE: ... Held tight !?

"Osisko or Richmont - one of them will make an appearance in the next month or so"

I seriously doubt it. The deal with Aurizon makes it very clear that the 5 million to be spent this year will be focused on trying to delineate an economically viable open-pit model as a first step, something that the shallow grades don't currently show clearly...

The big boys will likely wait until that information is out before making any decisions, and I suspect it's the same situation with the institutional investors. I think that means there will likely be no major movement (or news) until the fall.

Doesn't mean we won't see some stock appreciation due to retail investors though...

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario